Tag: Gilead Remdesivir

Jubilant gets rights to produce Gilead Remdesivir, a potential therapy for Covid-19 in 127 countries including India

by India CSR

Jubilant Generics Limited (Jubilant), has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that will grant Jubilant the ...

Facebook Twitter Youtube LinkedIn Instagram

India CSR is the largest tech-led platform for information on CSR and sustainability in India offering diverse content across multisectoral issues. It covers Sustainable Development, Corporate Social Responsibility (CSR), Sustainability, and related issues in India. Founded in 2009, the organisation aspires to become a globally admired media that offers valuable information to its readers through responsible reporting. To enjoy the premium services, we invite you to partner with us.

Subscribe to Our Newsletter

No Result

View All Result

Tag: Gilead Remdesivir

Jubilant gets rights to produce Gilead Remdesivir, a potential therapy for Covid-19 in 127 countries including India

Interviews

Didi Ki Dukaan is Helping Rural Women Become Independent Entrepreneurs: Vivek Prakash, Sr VP & Head–CSR, Jubilant Ingrevia

Responsible Business Must Turn Research into Real Impact: Prof Bob Doherty

DP World’s Sustainability Strategy: Building Greener, Inclusive Logistics in India

Every Premature Baby Deserves the Right to Sight: Dr. V.K. Raju, Chairman, Goutami Eye Institute & Founder, Eye Foundation of America

CSR UPDATES

Hindustan Zinc unveils Zinc Finisher Medal as Registrations Cross 7000 for the Vedanta Zinc City Half Marathon

CSR: Bank of Baroda supports Girl Child Education and Women’s Economic Empowerment in Sri Vijaya Puram

TREVOC Strengthens CSR With Recognition for Site Personnel and Safety Practices

Bannari Amman Sugars Spends Rs 4.28 Cr on CSR in FY 2025-26

Rachana Infrastructure Spends Rs. 9 Lakh on CSR in FY2025-26, Exceeds Mandatory Obligation

Shivam Chemicals Reports Nil CSR Expenditure for Second Straight Year; FY2025-26 Revenue Rises 30%

Subscribe to Our Newsletter